A realistic utilization of nanotechnology in molecular imaging and targeted radiotherapy of solid tumors

Radiation Research

Volumn 177, Issue 4, 2012, Pages 483-495

  Patel, Vivek ^a   Papineni, Rao V L ^b   Gupta, Seema ^a   Stoyanova, Radka ^a   Ahmed, Mansoor M ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b CARESTREAM HEALTH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; MOLECULAR IMAGING; MORBIDITY; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TREATMENT PLANNING;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DRUG CARRIERS; FLUORESCENT DYES; FLUOROMETRY; GADOLINIUM; HUMANS; MOLECULAR IMAGING; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; QUANTUM DOTS; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SPECTRUM ANALYSIS, RAMAN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 84859759191     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2597.1     Document Type: Review

References (121)

1. Dawson LA, Menard C. Imaging in radiation oncology: a perspective. Oncologist 2010; 15(4):338-49.
2. Hristov DaX, L. Medical Imaging Modalities in Radiotherapy. In: Lu JaB, L, editor. Radation Oncology: An Evidence-Based Approach. Germany: Springer; 2008. p. 625-40.
3. Minchin RF, Martin DJ. Nanoparticles for molecular imaging-an overview. Endocrinology 2010 Feb; 151(2):474-81.
4. Lietman SA, Joyce MJ. Bone sarcomas: Overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med 2010 Mar; 77 Suppl 1:S8-12.
5. Lloyd C, McHugh K. The role of radiology in head and neck tumours in children. Cancer Imaging 2010; 10:49-61.
6. Coutinho AC, Jr., Krishnaraj A, Pires CE, Bittencourt LK, Guimaraes AR. Pelvic applications of diffusion magnetic resonance images. Magn Reson Imaging Clin N Am 2011 Feb; 19(1):133-57.
7. Maier SE, Sun Y, Mulkern RV. Diffusion imaging of brain tumors. NMR Biomed 2010 Aug; 23(7):849-64.
8. de Carvalho Rangel C, Hygino Cruz LC, Jr., Takayassu TC, Gasparetto EL, Domingues RC. Diffusion MR imaging in central nervous system. Magn Reson Imaging Clin N Am 2011 Feb; 19(1):23-53.
9. Schafer J, Srinivasan A, Mukherji S. Diffusion magnetic resonance imaging in the head and neck. Magn Reson Imaging Clin N Am 2011 Feb; 19(1):55-67.
10. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 2006 Oct; 7(10):848-58. (Pubitemid 44464078)
11. Teh BS, Paulino A, Butler EB. [Recent developments in radiation oncology-integrating radiation physics and molecular radiobiology advances into clinical radiotherapy practice and beyond]. Ai Zheng 2008 Aug; 27(8):885-93.
12. Grimm J, Wunder A. [Current state of molecular imaging research]. Rofo 2005 Mar; 177(3):326-37. (Pubitemid 40363279)
13. Heneweer C, Grimm J. Clinical applications in molecular imaging. Pediatr Radiol 2010 Dec 3.
14. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol 2010 Jul; 65(7):500-16.
15. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular imaging techniques in body imaging. Radiology 2007 Nov; 245(2):333-56. (Pubitemid 47612513)
16. Thorwarth D, Geets X, Paiusco M. Physical radiotherapy treatment planning based on functional PET/CT data. Radiother Oncol 2010 Sep; 96(3):317-24.
17. Dijkgraaf I, Boerman OC. Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging 2010 Aug; 37 Suppl 1:S104-13.
18. Valotassiou V, Archimandritis S, Sifakis N, Papatriantafyllou J, Georgoulias P. Alzheimer's disease: spect and pet tracers for beta-amyloid imaging. Curr Alzheimer Res 2010 Sep 1; 7(6): 477-86.
19. Brom M, Andralojc K, Oyen WJ, Boerman OC, Gotthardt M. Development of radiotracers for the determination of the beta-cell mass in vivo. Curr Pharm Des 2010 May; 16(14):1561-7.
20. Ji SY, Travin MI. Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol 2010 Aug; 17(4):655-66.
21. Amen DG, Hanks C, Prunella J. Predicting positive and negative treatment responses to stimulants with brain SPECT imaging. J Psychoactive Drugs 2008 Jun; 40(2):131-8.
22. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010 Mar; 40(2):122-35.
23. Mariani G, Bruselli L, Kuwert T, Kim EE, Flotats A, Israel O, Dondi M, Watanabe N. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010 Oct; 37(10):1959-85.
24. Serkova NJ, Hasebroock KM, Kraft SL. Magnetic resonance spectroscopy of living tissues. Methods Mol Biol 2009; 520:315-27.
25. Blamek S, Larysz D, Ficek K, Sokol M, Miszczyk L, Tarnawski R. MR spectroscopic evaluation of brain tissue damage after treatment for pediatric brain tumors. Acta Neurochir Suppl 2010; 106:183-6.
26. Sharma N, Neumann D, Macklis R. The impact of functional imaging on radiation medicine. Radiat Oncol 2008; 3:25.
27. Zhang Y, Hong H, Cai W. Imaging with Raman spectroscopy. Curr Pharm Biotechnol 2010 Sep 1; 11(6):654-61.
28. Krafft C, Steiner G, Beleites C, Salzer R. Disease recognition by infrared and Raman spectroscopy. J Biophotonics 2009 Feb; 2(1-2):13-28.
29. Beljebbar A, Bouche O, Diebold MD, Guillou PJ, Palot JP, Eudes D, Manfait M. Identification of Raman spectroscopic markers for the characterization of normal and adenocarcinomatous colonic tissues. Crit Rev Oncol Hematol 2009 Dec; 72(3):255-64.
30. Candefjord S, Ramser K, Lindahl OA. Technologies for localization and diagnosis of prostate cancer. J Med Eng Technol 2009; 33(8):585-603.
31. Costamagna G, Marchese M. Progress in endoscopic imaging of gastrointestinal tumors. Eur Rev Med Pharmacol Sci 2010 Apr; 14(4):272-6.
32. Atuegwu NC, Gore JC, Yankeelov TE. The integration of quantitative multi-modality imaging data into mathematical models of tumors. Phys Med Biol 2010 May 7; 55(9):2429-49.
33. Vangestel C, Peeters M, Oltenfreiter R, D'Asseler Y, Staelens S, Van Steenkiste M, Philippe J, Kusters D, Reutelingsperger C, Van Damme N, Van de Wiele C. In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine- expressing cells. Nucl Med Biol 2010 Nov; 37(8):965-75.
34. Zimmermann M, Meyer N. Annexin V/7-AAD Staining in Keratinocytes. Methods Mol Biol 2011; 740:57-63.
35. Alencar H, Funovics MA, Figueiredo J, Sawaya H, Weissleder R, Mahmood U. Colonic adenocarcinomas: near-infrared microcatheter imaging of smart probes for early detection-study in mice. Radiology 2007 Jul; 244(1):232-8. (Pubitemid 46981978)
36. Gounaris E, Tung CH, Restaino C, Maehr R, Kohler R, Joyce JA, Ploegh HL, Barrett TA, Weissleder R, Khazaie K. Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One 2008; 3(8): e2916.
37. Figueiredo JL, Alencar H, Weissleder R, Mahmood U. Near infrared thoracoscopy of tumoral protease activity for improved detection of peripheral lung cancer. Int J Cancer 2006 Jun 1; 118(11):2672-7. (Pubitemid 43673343)
38. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, Ntziachristos V, Libby P, Weissleder R. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008 Oct 28; 118(18):1802-9.
39. Basu S, Kumar R, Alavi A. PET and PET-CT imaging in infection and inflammation: its critical role in assessing complications related to therapeutic interventions in patients with cancer. Indian J Cancer 2010 Oct-Dec; 47(4):371-9.
40. Mahfouz ME, Rodrigo JP, Takes RP, Elsheikh MN, Rinaldo A, Brakenhoff RH, Ferlito A. Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol 2010 Jun; 267(6):851-60.
41. Sattler B, Lee JA, Lonsdale M, Coche E. PET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning. Radiother Oncol 2010 Sep; 96(3):288-97.
42. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol 2010 Sep; 96(3):302-7.
43. Mitra A, Nan A, Line BR, Ghandehari H. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 2006; 12(36):4729-49. (Pubitemid 44841764)
44. Coleman CN. Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!). Radiology 2003 Jul; 228(1):29-35. (Pubitemid 36736066)
45. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010 Aug; 62(2):90-9.
46. Ting G, Chang CH, Wang HE, Lee TW. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010; 2010.
47. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004 Sep; 11(9):996-1004. (Pubitemid 39220809)
48. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 Jan; 1(1):27-31.
49. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003 Nov; 163(5): 1801-15. (Pubitemid 37310012)
50. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003 Jun; 9(6):713-25. (Pubitemid 36749220)
51. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41:189-207.
52. Ishida O, Maruyama K, Sasaki K, Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm 1999 Nov 10; 190(1):49-56. (Pubitemid 29467471)
53. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986 Dec; 46(12 Pt 1):6387-92. (Pubitemid 17221789)
54. Debbage P, Jaschke W. Molecular imaging with nanoparticles: giant roles for dwarf actors. Histochem Cell Biol 2008 Nov; 130(5):845-75.
55. Singhal S, Nie S, Wang MD. Nanotechnology applications in surgical oncology. Annu Rev Med 2010; 61:359-73.
56. Sokolov K, Follen M, Aaron J, Pavlova I, Malpica A, Lotan R, Richards-Kortum R. Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res 2003 May 1; 63(9):1999-2004. (Pubitemid 36538596)
57. El-Sayed IH, Huang X, El-Sayed MA. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett 2005 May; 5(5):829-34. (Pubitemid 40749040)
58. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem 2006 May-Jun; 17(3):603-9. (Pubitemid 43794369)
59. Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004 May-Jun; 11(3): 169-83. (Pubitemid 38720414)
60. Pope-Harman A, Cheng MM, Robertson F, Sakamoto J, Ferrari M. Biomedical nanotechnology for cancer. Med Clin North Am 2007 Sep; 91(5):899-927. (Pubitemid 47361211)
61. Jun YW, Jang JT, Cheon J. Magnetic nanoparticle assisted molecular MR imaging. Adv Exp Med Biol 2007; 620:85-106.
62. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008 Aug 17; 60(11): 1252-65.
63. Yang X, Skrabalak SE, Li ZY, Xia Y, Wang LV. Photoacoustic tomography of a rat cerebral cortex in vivo with au nanocages as an optical contrast agent. Nano Lett 2007 Dec; 7(12):3798-802.
64. De la Zerda A, Zavaleta C, Keren S, Vaithilingam S, Bodapati S, Liu Z, Levi J, Smith BR, Ma TJ, Oralkan O, Cheng Z, Chen X, Dai H, Khuri-Yakub BT, Gambhir SS. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008 Sep; 3(9):557-62.
65. Sharma P, Brown SC, Bengtsson N, Zhang Q, Walter GA, Grobmyer SR, Santra S, Jiang H, Scott EW, Moudgil BM. Gold-Speckled Multimodal Nanoparticles for Noninvasive Bioimaging. Chem Mater 2008 Oct 14; 20(19):6087-94.
66. McCarthy JR, Kelly KA, Sun EY, Weissleder R. Targeted delivery of multifunctional magnetic nanoparticles. Nanomedicine (Lond) 2007 Apr; 2(2):153-67. (Pubitemid 46850565)
67. Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005 Apr 27; 127(16):5732-3. (Pubitemid 40577599)
68. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J2007; 9(2):E128-47.
69. Phillips WT. Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev 1999 Apr 5; 37(1-3):13-32. (Pubitemid 29164497)
70. Boerman OC, Laverman P, Oyen WJ, Corstens FH, Storm G. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 2000 Sep; 39(5):461-75.
71. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001 Feb; 7(2):243-54. (Pubitemid 32183025)
72. Urakami T, Akai S, Katayama Y, Harada N, Tsukada H, Oku N. Novel amphiphilic probes for [18F]-radiolabeling preformed liposomes and determination of liposomal trafficking by positron emission tomography. J Med Chem 2007 Dec 27; 50(26):6454-7. (Pubitemid 350309083)
73. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004 Mar; 51(3):480-6. (Pubitemid 38298660)
74. Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 2006 Jan; 186(1):144-8. (Pubitemid 46100376)
75. Islam T, Harisinghani MG. Overview of nanoparticle use in cancer imaging. Cancer Biomark 2009; 5(2):61-7.
76. Zrazhevskiy P, Sena M, Gao X. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev 2010 Nov; 39(11):4326-54.
77. Rogach AL, Ogris M. Near-infrared-emitting semiconductor quantum dots for tumor imaging and targeting. Curr Opin Mol Ther 2010 Jun; 12(3):331-9.
78. Ma Q, Su X. Near-infrared quantum dots: synthesis, functionalization and analytical applications. Analyst 2010 Aug; 135(8): 1867-77.
79. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002 Oct 1; 99(20):12617-21.
80. Gao X, Dave SR. Quantum dots for cancer molecular imaging. Adv Exp Med Biol 2007; 620:57-73.
81. Biju V, Mundayoor S, Omkumar RV, Anas A, Ishikawa M. Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol Adv 2010 Mar-Apr; 28(2):199-213.
82. Baker JR, Jr. Dendrimer-based nanoparticles for cancer therapy. Hematology Am Soc Hematol Educ Program 2009:708-19.
83. Wijagkanalan W, Kawakami S, Hashida M. Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations. Pharm Res 2010 Dec 23.
84. Barrett T, Ravizzini G, Choyke PL, Kobayashi H. Dendrimers in medical nanotechnology. IEEE Eng Med Biol Mag 2009 Jan-Feb; 28(1):12-22.
85. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 2007; 14(1):77-91. (Pubitemid 46050305)
86. Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B. et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA 2009 Jan 20; 106(3):685-90.
87. Reimer P, Rummeny EJ, Daldrup HE, Balzer T, Tombach B, Berns T, Peters PE. Clinical results with Resovist: a phase 2 clinical trial. Radiology1995 May; 195(2):489-96.
88. Yoshikawa T, Mitchell DG, Hirota S, Ohno Y, Oda K, Maeda T. et al. Gradient-and spin-echo T2-weighted imaging for SPIOenhanced detection and characterization of focal liver lesions. J Magn Reson Imaging 2006 May; 23(5):712-9.
89. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, Takehara Y. et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol Mar; 45(3):133-41.
90. Savranoglu P, Obuz F, Karasu S, Coker A, Secil M, Sagol O. et al. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging 2006 Nov-Dec; 30(6):377-81. (Pubitemid 44709491)
91. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU. et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009 Jul-Aug; 33(4):301-5.
92. Curvo-Semedo L, Diniz M, Migueis J, Juliao MJ, Martins P, Pinto A. et al. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imaging 2006 Jul; 24(1):123-31.
93. Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P. et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 2003 Sep; 228(3):777-88. (Pubitemid 37025489)
94. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J2005 Mar; 19(3):311-30. (Pubitemid 40316520)
95. Medarova Z, Kumar M, Ng SW, Moore A. Development and application of a dual-purpose nanoparticle platform for delivery and imaging of siRNA in tumors. Methods Mol Biol2009; 555:1-13.
96. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med2007 Mar; 13(3):372-7. (Pubitemid 46376679)
97. Papineni RV, Ji T, McLaughlin W. US Patent Application Number 12/562184, 2010.
98. Papineni RV, Tao J, Udayakumar T, Shareef MM, Ahmed MM, Pollack A. Specificity in Gene Silencing Using Multifunctional Nanoparticles. World Molecular Imaging Society, Montreal, Canada, 2009
99. Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov 2007 Jun; 2(2):143-58. (Pubitemid 46952431)
100. Seigneuric R, Markey L, Nuyten DS, Dubernet C, Evelo CT, Finot E. et al. From nanotechnology to nanomedicine: applications to cancer research. Curr Mol Med Oct; 10(7):640-52.
101. Jacquin JP, Chargari C, Thorin J, Mille D, Melis A, Orfeuvre H. et al. Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients. Am J Clin Oncol Jan 26.
102. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF. et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009 Jun 1; 27(16):2592-7.
103. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN. et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res Apr 15; 16(8):2466-73.
104. Ting G, Chang CH, Wang HE. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res 2009 Oct; 29(10):4107-18.
105. Papineni RV, Tao J, Pan J. Fluorescence Quenching of Near-IR dye by Neutravidin PEGylated Gold Nanoparticles. World Molecular Imaging Congress; 2010; Kyoto, Japan 2010.
106. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004 Sep 21; 49(18):N309-15. (Pubitemid 39302700)
107. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol 2008 Aug; 60(8):977-85.
108. Cho SH, Jones BL, Krishnan S. The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/X-ray sources. Phys Med Biol 2009 Aug 21; 54(16):4889-905.
109. Chang MY, Shiau AL, Chen YH, Chang CJ, Chen HH, Wu CL. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci 2008 Jul; 99(7): 1479-84. (Pubitemid 351761741)
110. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, Curley SA. Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology 2008; 6:2.
111. Cardinal J, Klune JR, Chory E, Jeyabalan G, Kanzius JS, Nalesnik M, Geller DA. Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery2008 Aug; 144(2): 125-32. (Pubitemid 352010312)
112. Gannon CJ, Cherukuri P, Yakobson BI, Cognet L, Kanzius JS, Kittrell C. et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007 Dec 15; 110(12):2654-65. (Pubitemid 350250334)
113. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 2005 Apr; 5(4):709-11. (Pubitemid 40609745)
114. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001 Jan 1; 6(1):44-51. (Pubitemid 32156966)
115. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photothermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett 2004 Jun 25; 209(2):171-6. (Pubitemid 38670486)
116. Shiotani A, Akiyama Y, Kawano T, Niidome Y, Mori T, Katayama Y.et al. Active accumulation of gold nanorods in tumor in response to near-infrared laser irradiation. Bioconjug Chem 2010 Nov 17; 21(11):2049-54.
117. Goodrich GP, Bao L, Gill-Sharp K, Sang KL, Wang J, Payne JD. Photothermal therapy in a murine colon cancer model using nearinfrared absorbing gold nanorods. J Biomed Opt Jan-Feb; 15(1): 018001.
118. Dickerson EB, Dreaden EC, Huang X, El-Sayed IH, Chu H, Pushpanketh S, McDonald JF, El-Sayed MA. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett 2008 Sep 28; 269(1):57-66.
119. Huang N, Wang H, Zhao J, Lui H, Korbelik M, Zeng H. Singlewall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma. Lasers Surg Med Nov; 42(9):638-48.
120. Moon HK, Lee SH, Choi HC. In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano 2009 Nov 24; 3(11):3707-13.
121. Burke A, Ding X, Singh R, Kraft RA, Levi-Polyachenko N, Rylander MN. et al. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci USA 2009 Aug 4; 106(31):12897-902.